Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series

Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series

Background: Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited. Methods: This retrospective study evaluated 1...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuichi Abe, Dhammika Leshan Wannigama, Yu Suzuki, Daisuke Akaneya, Junko Igarashi, Mayu Suto, Kazunori Moriya, Daisuke Ishizawa, Yoshikazu Okuma, Parichart Hongsing, Cameron Hurst, Thammakorn Saethang, Paul G. Higgins, Stephen M. Stick, Anthony Kicic
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:New Microbes and New Infections
Online Access:http://www.sciencedirect.com/science/article/pii/S2052297524003068
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2052297524003068

Similar Items